Allarity settles SEC probe over FDA disclosures; pays $2.5M civil penalty

Allarity Therapeutics, Inc.

Final settlement with SEC: administrative cease-and-desist order, no admission or denial of findings.
Civil penalty of $2.5 million; cash runway into 2026 unchanged per prior guidance.
Resolves investigation into past disclosures about FDA interactions regarding Dovitinib NDA (2021).
All outstanding legal matters now concluded, including securities class action dismissed Feb 2025.
Company reaffirms focus on stenoparib Phase 2 trials in ovarian and small cell lung cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.